The Disappointment of the NSABP C-08 Trial
Norman Wolmark
/
RSS Feed
Norman Wolmark
Norman Wolmark on the study’s frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/090914NormWomarkNiPetrelliPODCAST.mp3]
You may also like...
Superior Survival in Conservatively Treated Male Breast Cancer 13 Jul, 2018 - Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer 11 Oct, 2018
- Adjuvant Checkpoint Inhibition Extends Disease-Free and Overall Survival in Patients with Stage III Melanoma 13 Oct, 2016
Younger than 35 with breast cancer: always consider neoadjuvant chemotherapy 18 Dec, 2012
